Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells
from the toxic effects of chemotherapy. It is not known whether enalapril is more effective
than a placebo in treating heart damage in patients who received anthracycline chemotherapy
for childhood cancer.
PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril
with a placebo in treating heart damage in patients who received anthracycline chemotherapy
for childhood cancer.